Over 35 years of experience in biopharma discovery and development.
Retired as CSO of Agios Pharmaceuticals at the end of 2019, a position he held for over 9 years. At Agios, Dr. Biller led efforts to discover two approved medicines, TIBSOVO® and IDHIFA® for AML harboring IDH1 and IDH2 mutations, respectively, a third, mitapivat (for pyruvate kinase deficiency) that recently completed two positive Phase 3 trials and a fourth, vorasidenib (for IDH-mutated low-fgrade glioma) which is currently in Phase 3.
Prior to Agios, Dr. Biller held senior R&D leadership roles at Novartis and BMS.
B.S. in chemistry from MIT, Ph.D. in organic chemistry from Caltech, NIH Postdoctoral Fellowship at Columbia University.